Selected research
Industry Research
Influenza Treatment Industry Research Report 2026
Market perspective
The global Influenza Treatment market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Influenza Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Influenza Treatment market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Influenza Treatment market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Influenza Treatment include Sanofi, Novartis AG, GSK plc., Daiichi Sankyo, AstraZeneca, Viatris Inc. (Mylan), Teva Pharmaceutical Industries Ltd., Roche Holding and NATCO Pharma Limited, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Influenza Treatment market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Influenza Treatment.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Influenza Treatment Market by Company
Sanofi
Novartis AG
GSK plc.
Daiichi Sankyo
AstraZeneca
Viatris Inc. (Mylan)
Teva Pharmaceutical Industries Ltd.
Roche Holding
NATCO Pharma Limited
Gilead Sciences
BioCryst Pharmaceuticals
Influenza Treatment Segment by Type
Zanamivir
Peramivir
Oseltamivir Phosphate
Baloxavir Marboxil
Others
Influenza Treatment Segment by Application
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Influenza Treatment Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Influenza Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Influenza Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Influenza Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Influenza Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Zanamivir
- Peramivir
- Oseltamivir Phosphate
- Baloxavir Marboxil
- Others
Applications
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
Companies covered
- Sanofi
- Novartis AG
- GSK plc.
- Daiichi Sankyo
- AstraZeneca
- Viatris Inc. (Mylan)
- Teva Pharmaceutical Industries Ltd.
- Roche Holding
- NATCO Pharma Limited
- Gilead Sciences
- BioCryst Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Influenza Treatment by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Zanamivir
- 2.2.3 Peramivir
- 2.2.4 Oseltamivir Phosphate
- 2.2.5 Baloxavir Marboxil
- 2.2.6 Others
- 2.3 Influenza Treatment by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital Pharmacies
- 2.3.3 Online Pharmacies
- 2.3.4 Retail Pharmacies
- 2.4 Assumptions and Limitations
3 Influenza Treatment Breakdown Data by Type
- 3.1 Global Influenza Treatment Historic Market Size by Type (2021-2026)
- 3.2 Global Influenza Treatment Forecasted Market Size by Type (2027-2032)
4 Influenza Treatment Breakdown Data by Application
- 4.1 Global Influenza Treatment Historic Market Size by Application (2021-2026)
- 4.2 Global Influenza Treatment Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Influenza Treatment Market Perspective (2021-2032)
- 5.2 Global Influenza Treatment Growth Trends by Region
- 5.2.1 Global Influenza Treatment Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Influenza Treatment Historic Market Size by Region (2021-2026)
- 5.2.3 Influenza Treatment Forecasted Market Size by Region (2027-2032)
- 5.3 Influenza Treatment Market Dynamics
- 5.3.1 Influenza Treatment Industry Trends
- 5.3.2 Influenza Treatment Market Drivers
- 5.3.3 Influenza Treatment Market Challenges
- 5.3.4 Influenza Treatment Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Influenza Treatment Players by Revenue
- 6.1.1 Global Top Influenza Treatment Players by Revenue (2021-2026)
- 6.1.2 Global Influenza Treatment Revenue Market Share by Players (2021-2026)
- 6.2 Global Influenza Treatment Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Influenza Treatment Head Office and Area Served
- 6.4 Global Influenza Treatment Players, Product Type & Application
- 6.5 Global Influenza Treatment Manufacturers Established Date
- 6.6 Global Influenza Treatment Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Influenza Treatment Market Size (2021-2032)
- 7.2 North America Influenza Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Influenza Treatment Market Size by Country (2021-2026)
- 7.4 North America Influenza Treatment Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Influenza Treatment Market Size (2021-2032)
- 8.2 Europe Influenza Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Influenza Treatment Market Size by Country (2021-2026)
- 8.4 Europe Influenza Treatment Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Influenza Treatment Market Size (2021-2032)
- 9.2 Asia-Pacific Influenza Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Influenza Treatment Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Influenza Treatment Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Influenza Treatment Market Size (2021-2032)
- 10.2 South America Influenza Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Influenza Treatment Market Size by Country (2021-2026)
- 10.4 South America Influenza Treatment Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Influenza Treatment Market Size (2021-2032)
- 11.2 Middle East & Africa Influenza Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Influenza Treatment Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Influenza Treatment Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Sanofi
- 12.1.1 Sanofi Company Information
- 12.1.2 Sanofi Business Overview
- 12.1.3 Sanofi Revenue in Influenza Treatment Business (2021-2026)
- 12.1.4 Sanofi Influenza Treatment Product Portfolio
- 12.1.5 Sanofi Recent Developments
- 12.2 Novartis AG
- 12.2.1 Novartis AG Company Information
- 12.2.2 Novartis AG Business Overview
- 12.2.3 Novartis AG Revenue in Influenza Treatment Business (2021-2026)
- 12.2.4 Novartis AG Influenza Treatment Product Portfolio
- 12.2.5 Novartis AG Recent Developments
- 12.3 GSK plc.
- 12.3.1 GSK plc. Company Information
- 12.3.2 GSK plc. Business Overview
- 12.3.3 GSK plc. Revenue in Influenza Treatment Business (2021-2026)
- 12.3.4 GSK plc. Influenza Treatment Product Portfolio
- 12.3.5 GSK plc. Recent Developments
- 12.4 Daiichi Sankyo
- 12.4.1 Daiichi Sankyo Company Information
- 12.4.2 Daiichi Sankyo Business Overview
- 12.4.3 Daiichi Sankyo Revenue in Influenza Treatment Business (2021-2026)
- 12.4.4 Daiichi Sankyo Influenza Treatment Product Portfolio
- 12.4.5 Daiichi Sankyo Recent Developments
- 12.5 AstraZeneca
- 12.5.1 AstraZeneca Company Information
- 12.5.2 AstraZeneca Business Overview
- 12.5.3 AstraZeneca Revenue in Influenza Treatment Business (2021-2026)
- 12.5.4 AstraZeneca Influenza Treatment Product Portfolio
- 12.5.5 AstraZeneca Recent Developments
- 12.6 Viatris Inc. (Mylan)
- 12.6.1 Viatris Inc. (Mylan) Company Information
- 12.6.2 Viatris Inc. (Mylan) Business Overview
- 12.6.3 Viatris Inc. (Mylan) Revenue in Influenza Treatment Business (2021-2026)
- 12.6.4 Viatris Inc. (Mylan) Influenza Treatment Product Portfolio
- 12.6.5 Viatris Inc. (Mylan) Recent Developments
- 12.7 Teva Pharmaceutical Industries Ltd.
- 12.7.1 Teva Pharmaceutical Industries Ltd. Company Information
- 12.7.2 Teva Pharmaceutical Industries Ltd. Business Overview
- 12.7.3 Teva Pharmaceutical Industries Ltd. Revenue in Influenza Treatment Business (2021-2026)
- 12.7.4 Teva Pharmaceutical Industries Ltd. Influenza Treatment Product Portfolio
- 12.7.5 Teva Pharmaceutical Industries Ltd. Recent Developments
- 12.8 Roche Holding
- 12.8.1 Roche Holding Company Information
- 12.8.2 Roche Holding Business Overview
- 12.8.3 Roche Holding Revenue in Influenza Treatment Business (2021-2026)
- 12.8.4 Roche Holding Influenza Treatment Product Portfolio
- 12.8.5 Roche Holding Recent Developments
- 12.9 NATCO Pharma Limited
- 12.9.1 NATCO Pharma Limited Company Information
- 12.9.2 NATCO Pharma Limited Business Overview
- 12.9.3 NATCO Pharma Limited Revenue in Influenza Treatment Business (2021-2026)
- 12.9.4 NATCO Pharma Limited Influenza Treatment Product Portfolio
- 12.9.5 NATCO Pharma Limited Recent Developments
- 12.10 Gilead Sciences
- 12.10.1 Gilead Sciences Company Information
- 12.10.2 Gilead Sciences Business Overview
- 12.10.3 Gilead Sciences Revenue in Influenza Treatment Business (2021-2026)
- 12.10.4 Gilead Sciences Influenza Treatment Product Portfolio
- 12.10.5 Gilead Sciences Recent Developments
- 12.11 BioCryst Pharmaceuticals
- 12.11.1 BioCryst Pharmaceuticals Company Information
- 12.11.2 BioCryst Pharmaceuticals Business Overview
- 12.11.3 BioCryst Pharmaceuticals Revenue in Influenza Treatment Business (2021-2026)
- 12.11.4 BioCryst Pharmaceuticals Influenza Treatment Product Portfolio
- 12.11.5 BioCryst Pharmaceuticals Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst